Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Total Liabilities (2016 - 2025)

Orthofix Medical (OFIX) has disclosed Total Liabilities for 16 consecutive years, with $400.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 2.68% year-over-year to $400.6 million, compared with a TTM value of $400.6 million through Dec 2025, up 2.68%, and an annual FY2025 reading of $400.6 million, up 2.68% over the prior year.
  • Total Liabilities was $400.6 million for Q4 2025 at Orthofix Medical, up from $390.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $400.6 million in Q4 2025 and bottomed at $116.1 million in Q3 2022.
  • Average Total Liabilities over 5 years is $256.4 million, with a median of $275.7 million recorded in 2023.
  • The sharpest move saw Total Liabilities tumbled 44.26% in 2021, then surged 168.2% in 2023.
  • Year by year, Total Liabilities stood at $139.7 million in 2021, then dropped by 12.83% to $121.8 million in 2022, then soared by 168.2% to $326.6 million in 2023, then grew by 19.47% to $390.2 million in 2024, then increased by 2.68% to $400.6 million in 2025.
  • Business Quant data shows Total Liabilities for OFIX at $400.6 million in Q4 2025, $390.1 million in Q3 2025, and $378.8 million in Q2 2025.